Table 2.
The effect of imipramine (IMP) on sphingomyelin (SM) content in macrophages treated with LPS, PA or LPS plus PA
| Treatment | IMP | C16-SM | C18-SM | C20-SM | C22-SM | C24-SM | C24:1-SM | Total SM |
|---|---|---|---|---|---|---|---|---|
| Control | − IMP | 31.79±4.54 | 1.85±0.27 | 0.62±0.09 | 3.27±0.47 | 2.36±0.34 | 6.56±0.94 | 50.32±7.19¶ |
| + IMP | 31.85±7.19 | 2.15±0.31 | 0.72±0.10 | 3.57±0.51 | 2.24±0.32 | 5.80±0.83 | 49.90±7.13 | |
| LPS | − IMP | 31.18±4.46 | 1.45±0.21 | 0.51±0.07 | 2.56±0.37 | 1.88±0.27 | 4.82±0.69 | 46.29±6.61# |
| + IMP | 30.09±4.30 | 1.77±0.25 | 0.57±0.08 | 2.84±0.41 | 2.23±0.32 | 4.31±0.62 | 45.01±6.43 | |
| PA | − IMP | 24.78±3.54 | 3.95±3.54 | 1.24±0.18 | 5.58±0.80 | 2.37±0.34 | 6.42±0.92 | 47.30±6.76^ |
| + IMP | 31.07±4.44 | 3.63±0.52 | 1.01±0.15 | 4.66±0.67 | 2.1±0.30 | 6.31±0.90 | 51.84±7.41 | |
| LPS+PA | − IMP | 17.59±2.51 | 2.06±0.30 | 0.60±0.09 | 2.57±0.37 | 1.07±0.15 | 3.89±0.56 | 29.68±4.24* |
| + IMP | 28.59±4.09 | 2.58±0.37 | 0.76±0.11 | 3.29±0.47 | 1.470.21 | 5.45±0.78 | 44.93±6.42+ |
Raw264.7 cells were treated with 1 ng/ml of LPS, 100 μM of PA or both LPS and PA in the presence or absence of 50 μM of IMP for 12 h. After treatment, cells were harvested and subjected to the lipidomic analysis of SMs as described in Methods. The unit of the values is pmol/nmol Pi. IMP, imipramine; SM, sphingomyelin; PA, palmitic acid.
*
p<0.01 vs +, ¶, # or ^.